Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first oral therapy

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

New health ministers and re-appointments after reshuffle

Industry sees both continuity and change after the UK’s General Election

Roche Basel Switzerland

Roche moves closer to US filing for alectinib

Results showed alectinib able to shrink tumours in half of cases

- PMLiVE

George Freeman re-appointed as UK life science minister

Industry welcomes his continuation in this pharma-focused role

- PMLiVE

Cancer drug spend tops $100bn in 2014

But payers are starting to bulk at increasing prices

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

- PMLiVE

Is a UK market access shake-up on the cards?

Former coalition government health minister Paul Burstow tells PMLiVE that NICE, QALY and broader issues of market access in England are all being put under review

Roche Basel Switzerland

Roche maintains top place in biologic sales

But the looming threat of biosimilars is set to shake up the market

Roche Basel Switzerland

Roche adds kidney cancer to anti-PD-L1 programme

Inhibitor already indicated for lung, bladder and breast cancer

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

Roche Basel Switzerland

Trials of Roche’s new blindness candidate now underway

Lampalizumab in phase III for age-related maculardegeneration

- PMLiVE

Avastin approved for cervical cancer in EU

Was approved for the same indication in the US last summer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links